Wednesday newspaper round-up: AstraZeneca, SSE, IMF...
8th Jan 2014 07:19
AstraZeneca has struck a deal with a fast-growing UK biotech company to develop treatments that use the body's immune system to fight cancer. The partnership with privately owned Immunocore highlights intensifying interest from big pharmaceutical groups in what many experts consider the most promisi
Read moreLondon open: Retailers give markets a boost after Boxing Day sales
27th Dec 2013 09:22
- IPF plummets after news of Polish fine - Shoppers hit the streets for Boxing Day sales - US jobless claims drop by 42,000 techMARK 2,776.01 +0.26% FTSE 100 6,724.97 +0.46% FTSE 250 15,801.26 +0.12% UK markets headed higher on Friday morning, reopening strongly after the Christmas holidays, as in
Read moreAstraZeneca reduces Crestor royalty rates with Shionogi
27th Dec 2013 08:27
Pharmaceuticals group AstraZeneca has settled arbitration proceedings with Japanese group Shionogi & Co over the calculation of royalties related to its cholesterol treatment Crestor. As part of the agreement, payments from Astra to Shionogi have been adjusted to reduce the royalty rate in 2014-20
Read moreFriday tips round-up: AstraZeneca, Vodafone
20th Dec 2013 14:24
New AstraZeneca Chief Pascal Soriot made another decisive move on Thursday to return the company quickly back to growth, by acquiring the 50 per cent he did not already own of the firm's global diabetes joint-venture with Brystol Myers Squibb for 4.3bn dollars. The disease, which now afflicts 350m p
Read moreLondon close: Stocks surge to two-and-a-half-week high after Fed taper
19th Dec 2013 16:31
- FTSE 100 at highest since December 2nd after Fed taper - Fed scales back stimulus, gives guidance on rates - Carnival jumps late on after FY results - Pharmaceutical and life insurance stocks rise techMARK 2,735.02 +1.40% FTSE 100 6,584.70 +1.43% FTSE 250 15,589.95 +1.45% UK stocks surged to a t
Read moreFTSE 100 movers: Carnival buoyed by Q4 results, drugmakers higher
19th Dec 2013 14:47
Cruise operator Carnival surged into the top spot on the FTSE 100 risers list on Thursday after reporting a smaller-than-expected decline in net revenue yields in the fourth quarter. Net revenue yields in constant dollars fell by 2.1 per cent year-on-year, better than the company's guidance given in
Read moreAberdeen Deputy CEO trousers 5.4m pounds as shares 10-year high
19th Dec 2013 14:39
It was revealed that Aberdeen Asset Management's Deputy Chief Executive Officer (CEO) Andrew Laing sold 2.6m pounds in shares earlier this week as well as selling 2.7m pounds-worth of new shares awarded in his long-term bonus plan. Aberdeen shares recently hit heights not seen since 2001. Down th
Read moreLondon midday: Markets jump one per cent after Fed taper
19th Dec 2013 12:01
- Fed tapers monthly asset purchases by 10bn dollars - Markets rise, Wall Street hits record high - Annual growth of UK retail sales misses estimates techMARK 2,732.70 +1.31% FTSE 100 6,556.63 +0.99% FTSE 250 15,576.80 +1.37% UK markets had held on to their gains by Thursday lunchtime as investors
Read moreBroker snap: Generics threat tightens breathing room at Glaxo, says Jefferies
19th Dec 2013 10:10
Jefferies has maintained its 'hold' rating for GlaxoSmithKline (GSK) after Denmark approved the sale of a generic copy of its top-selling inhaled lung drug, Advair. It was announced on Thursday that Novartis' Sandoz and Vectura have been given the green light by Danish authorities for the V315 AirF
Read moreAstraZeneca buys out Bristol in diabetes alliance for up to 4.1bn dollars
19th Dec 2013 09:15
- 2.7bn dollars on completion, 1.4bn in future payments - Provides 'platform for returning AstraZeneca to growth', says CEO AstraZeneca is to spend up to 4.1bn dollars for Bristol-Myers Squibb's stake in their diabetes joint venture, giving the British pharmaceuticals company full ownership of a la
Read moreThursday broker round-up UPDATE
19th Dec 2013 08:27
AstraZeneca: Alphavalue lowers target price from 3169p to 3087.7p and downgrades from reduce to sell. British American Tabacco: Panmure Gordon reduces target price from 3800p to 3200p and downgrades from buy to hold. Britvic: Investec ups target price from 600p to 672p and maintains a hold recomme
Read moreLondon open: Fed taper sparks 'Santa Rally' as stocks jump
19th Dec 2013 08:17
- Fed cuts monthly bond buying to 75bn dollars - Commits to near-zero rates, depending on inflation - Pharma peers AstraZeneca, GSK making gains techMARK 2,727.60 +1.12% FTSE 100 6,553.38 +0.94% FTSE 250 15,550.52 +1.20% UK markets opened around one per cent higher on Thursday morning in the after
Read moreGlaxo COPD approval cooled by generic Advair competition
19th Dec 2013 07:58
US regulators have approved GlaxoSmithKline's treatment for chronic obstructive pulmonary disease, but the excitement was cooled by news that Denmark has approved the sale of a generic copy of GSK's biggest product, Advair. On Wednesday evening Glaxo and Theravance announced that the US Food and Dr
Read moreTuesday broker round-up UPDATE
17th Dec 2013 08:14
Advanced Medical Solutions: Panmure Gordon downgrades from buy to hold with a target price of 102p. Antofagasta: Canaccord Genuity cuts target price from 1110p to 1035p, while staying with its buy recommendation. ASOS: Panmure Gordon increases target price from 5950p to 6126p, while downgrading fr
Read moreFTSE 100 movers: RSA slumps on earnings downgrade
13th Dec 2013 15:44
RSA Insurance fell sharply from the off after lowering its 2013 earnings forecast after identifying issues in its Irish business and experiencing adverse weather in Europe. At the same time the group announced the resignation of group Chief Executive Simon Lee with immediate effect. Temporary powe
Read more